Table 1. The correlation between TUSC8 expression and clinicopathological characteristics of breast cancer patients.
| Parameters | TUSC8 expression | P * | |||
| High (N=32) | Low (N=32) | ||||
| Age (years) | 0.089 | ||||
| >60 | 12 | (18.8%) | 19 | (29.7%) | |
| <=60 | 20 | (31.2%) | 13 | (20.3%) | |
| Tumor size | 0.0009* | ||||
| >5cm | 10 | (15.6%) | 24 | (37.5%) | |
| <=5cm | 22 | (34.4%) | 8 | (12.5%) | |
| Molecular subtype | 0.489 | ||||
| Luminal A/B | 11 | (17.2%) | 8 | (12.5%) | |
| HER2+ | 12 | (18.8%) | 10 | (15.6%) | |
| Basal-like | 9 | (14.1%) | 14 | (21.8%) | |
| Tumor encapsulation | 0.005* | ||||
| Presence | 21 | (32.8%) | 9 | (14.1%) | |
| Absence | 11 | (17.2%) | 23 | (35.9%) | |
| Venous invasion | 0.002* | ||||
| Presence | 9 | (14.1%) | 22 | (34.4%) | |
| Absence | 23 | (35.9%) | 10 | (15.6%) | |
| TNM staging | 0.002* | ||||
| I-II | 20 | (31.2%) | 7 | (10.9%) | |
| III-IV | 12 | (18.8%) | 25 | (39.1%) | |
* Fisher exact test.